Similarly, RB1 loss and high p16Ink4a levels confer resistance to Palbociclib, a selective CDK4/6 inhibitor showing promising clinical results in ER + BC (O’Leary et al. 2016). This evidence concerns the gene CDK4 and breast cancer.